Prana Biotechnology (PRAN) Upgraded to “Buy” by ValuEngine

ValuEngine upgraded shares of Prana Biotechnology (NASDAQ:PRAN) from a hold rating to a buy rating in a report published on Thursday.

Prana Biotechnology stock traded up $0.05 during trading hours on Thursday, reaching $1.93. 36,165 shares of the stock were exchanged, compared to its average volume of 39,017. Prana Biotechnology has a 52-week low of $1.75 and a 52-week high of $3.79.

About Prana Biotechnology

Prana Biotechnology Ltd. engages in the development of therapy treatment for neurodegenerative disease. It includes research and development of treatments for Alzheimer’s and Huntington’s disease. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Parkville, Australia.

See Also: Penny Stocks, Risk and Reward Factors

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Prana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply